For more information about each sponsor, please click on their logo.
Canadian Partnership Against Cancer (CPAC)
The Partnership works with cancer control partners from across Canada to achieve our shared goal of a future in which fewer Canadians get cancer, fewer die from it and those living with the disease have a better quality of life.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc., Kenilworth, NJ, USA). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China.
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Roche concentrates exclusively on innovative medicines and diagnostic approaches that offer decisive advantages over existing products and solutions. Our aim is to continue tailoring medicine as closely as possible to patients’ needs. As one of the world’s leading healthcare companies, and given our combined strengths in pharmaceuticals and diagnostics, there’s no one better suited for the task of developing personalised medicine.
American Cancer Society
The American Cancer Society is a global grassroots force of 2.5 million volunteers saving lives and fighting for every birthday threatened by every cancer in every community. As the largest voluntary health organization in the US, the Society's efforts have contributed to a 22 percent decline in cancer death rates in the U.S. since 1991, and a 50 percent drop in smoking rates. Thanks in part to our progress; 14.5 million Americans who have had cancer and countless more who have avoided it will celebrate more birthdays this year. We are determined to finish the fight against cancer. We are finding cures as the nation's largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings, clean air, and more. For more information, to get help, or to join the fight, call us anytime, day or night, at +1-800-227-2345 or visit cancer.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments for patients in areas of high unmet medical need. Our oncology research is driven by a passion to improve the lives of patients who are battling cancer and a determination for cancer to eventually be treated as a chronic condition. We seek out strong partnerships and remain dedicated to expanding our portfolio of treatments in both solid tumours and haematological cancers. We are proud of our unique approach to research and discovery which is currently focused on angiogenesis inhibition, signal transduction inhibition, cell-cycle kinase inhibition, immunotherapy, apoptosis, epigenetics and protein homeostasis.
European Federation of Pharmaceutical Industries and Associations (EFPIA)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information, visit www.novartisoncology.com.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Astellas’ business philosophy states that its raison d’être is to “contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products,” and its mission is “sustainable enhancement of enterprise value.” To realize this, we believe, means to earn the trust of patients and all other stakeholders, and to be their company of choice.
We push the boundaries of science to deliver life-changing medicines. Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators. We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.
Bloomberg Philanthropies’ mission is to ensure better, longer lives for the greatest number of people. The organization focuses on five key areas for creating lasting change: Public Health, Environment, Education, Government Innovation and the Arts. Bloomberg Philanthropies encompasses all of Michael R. Bloomberg’s charitable activities, including his foundation and his personal giving. In 2015, Bloomberg Philanthropies distributed $510 million.
Breast Cancer Initiative (BCI2.5)
Aim The Breast Cancer Initiative (BCI2.5) is a global campaign to reduce disparities in breast cancer outcomes for 2.5 million women by 2025. About BCI2.5 AIM BCI2.5 represents a new commitment to unite the global breast cancer community behind a common goal to make breast health a global priority and reduce disparities in breast cancer outcomes worldwide. The initiative began as a call for action in 2014 supported by the American Cancer Society, Susan G. Komen and the Union for International Cancer Control. Since that initial pledge, BCI2.5 has been engaging partners around the world, assessing need, identifying priorities and defining a strategy to meet this goal. Its consensus-based approach empowers regional champions to bring about change with the aid of BCI2.5 analytic, assessment and planning tools, educational materials and implementation science research methodology. BCI2.5 delivers evidence-based technical expertise and a resource-stratified approach to improving breast health services and care at any resource level. The initiative is inclusive and encourages organizations, institutions and countries to connect and join the effort.
Cancer Research UK (CRUK)
Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.
Center for Disease Control
CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. Whether diseases start at home or abroad, are chronic or acute, curable or preventable, human error or deliberate attack, CDC fights disease and supports communities and citizens to do the same. CDC increases the health security of our nation. As the nation’s health protection agency, CDC saves lives and protects people from health threats. To accomplish our mission, CDC conducts critical science and provides health information that protects our nation against expensive and dangerous health threats, and responds when these arise.
Chinese Anti-Cancer Association (CACA)
Established in 1984, the Chinese Anti-Cancer Association (CACA) is a non-government and non- profit organization. CACA is dedicated to increase the survival rate, decrease the incidence and mortality rates of cancer, and improve the cancer control in China. CACA plays an important role in promoting academic exchange, organizing public education, establishing collaboration with international cancer societies, and providing data and advices to the Chinese government for making strategies and policies on cancer control. The branches are consist of 45 professional societies, 47 full membership organizations, and 30 local anti-cancer associations with a total membership exceeding 47,000.
DITTA is the united global industry voice for diagnostic imaging, radiation therapy, healthcare ICT, electromedical and radiopharmaceuticals, representing more than 600 medical technology manufacturers, committed to improving health care and patient outcomes. DITTA was created in 2001 and incorporated In 2012 as a non-profit trade association in order to allow growth and enable partnerships with global organisations. Since its inception, membership has grown significantly, and today counts ten regional associations around the globe amongst its members. In 2015, DITTA granted the NGO status in official relations with the World Health Organization and signed a Memorandum of Understanding with the World Bank in 2016.
GE Healthcare is an $18 billion unit of General Electric (NYSE: GE) that provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
Institut Curie, a major player in the fight against cancer, is a private foundation granted charitable status accepting public donations and legacy gifts. Based is the Paris area (Paris, Orsay, Saint-Cloud), it comprises an internationally renowned cancer research center and a leading-edge hospital group, a pioneer in precision medicine that cares for patients diagnosed with all types of cancer including rare ones. Institut Curie was founded in 1909 on a model devised by Marie Curie, twice winner of the Nobel Prize, and still at the cutting edge: "from fundamental research to innovative treatments". Its 3,300 staff are all devoted to the institute’s missions that include treatment and research for the benefit of cancer patients, training and education as well as conservation of scientific heritage. In 2011 Institut Curie became a founding member of PSL Research University Paris. Find out more on curie.fr
Institut National du Cancer (INCA)
The French National Cancer Institute is a health and science agency dedicated to cancer. Placed under the umbrella of the Ministries of Health and Research, it brings together all of the players involved in the fight against cancer in France, to enable a long-lasting, coordinated national policy against cancer. It operates on an interdisciplinary basis, with the aim of federating, uniting and mobilising players and resources around joint projects. The Institute is a public expertise agency (produces or co produces regulatory documents) whose means of actions are the implementation of partnerships with and through the existing public and/or private structures of Care, Public Health and Research, and calls for proposals. The Institute covers the whole spectrum of the fight against cancer and has four main areas of interventions: - Public Health - Care - Research - Public information The Institute's aspiration is to help lower mortality due to cancer and improve the quality of living for people with cancer. The Institute has been a full UICC member since 2006.
Our vision Improve the lives of patients – Become a leader in the treatment of targeted debilitating diseases. Our ambition Be respected above all for our strategic model, our success and our commitment – Be among the top 10 pharmaceutical companies in the world by 2020 in terms of growth and profitability.
Norwegian Cancer Society
NCS is an active civil society actor which contributes to targeted efforts in cancer information, prevention, advocacy, research, care, and international cooperation. Our activities are funded thanks to the contributions of our members, bequests, and allocations form the national lottery funds. Our main objectives are to: Contribute to ensure that fewer people develop cancer (reduction of the prevalence and incidence of cancer) Contribute to more people surviving cancer Ensure the best quality of life for people affected by cancer (cancer patients and their relatives) Our vision: Together we create hope
Prevent Cancer Foundation
The mission of the Prevent Cancer Foundation is saving lives across all populations through cancer prevention and early detection. Vision: Stop Cancer Before It Starts!™ Reducing the cancer mortality rate by focusing individual behaviors, public policy, and research on prevention and early detection, Addressing all preventable cancers across all populations, Making prevention knowledge and early detection services more accessible for people in medically underserved communities, Collaborating with partners to maximize the effectiveness and reach of the prevention and early detection programs and message, Creating an energizing and productive workplace that people want to join
Susan G. Komen
In 1980, Nancy G. Brinker promised her dying sister, Susan, that she would do everything in her power to end breast cancer forever. In 1982, that promise became the Susan G. Komen® organization and the beginning of a global movement. What was started with $200 and a shoebox full of potential donor names has now grown into the world’s largest nonprofit source of funding for the fight against breast cancer. To date, we’ve invested more than $2.6 billion in groundbreaking research, community health outreach, advocacy and programs in more than 60 countries. Our efforts helped reduce death rates from breast cancer by 37 percent between 1990-2013; and have helped improve the five-year relative survival rate for early stage cancers in the U.S. from about 74 to 99 percent. And we won’t stop until our promise is fulfilled.
The UNICANCER Group brings together the French Comprehensive Cancer Centers (FCCC), promotes their cancer research organisation and pools resources and competencies to give a new dynamic to patient care. Since their creation in 1945, the French Comprehensive Cancer Centers have held a special place in the French health care system. These private, non-profit establishments are entirely devoted to fighting cancer with a view to public service. They have a threefold mission: patient care, research and teaching. UNICANCER builds on the historical community of the FCCC and accentuates what has always been their strength: cooperating and creating synergies between different teams within the network.
ecancer is an open access publisher and online education channel. The organisation is committed to improving cancer communication and education with the goal of optimising patient care and outcomes. The ecancer platform is home to: ecancermedicalscience, News, Video library, Conferences, e-learning. ecancer is supported by the ECMS foundation. The foundation was established by Professor Umberto Veronesi and Professor Gordon McVie as an independent, not-for-profit organisation with charitable status to fund the speedy dissemination of cancer information.